Literature DB >> 29872554

Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity.

Lee-Hwa Tai1, Almohanad A Alkayyal1,2,3, Amanda L Leslie1, Shalini Sahi1, Sean Bennett1,4, Christiano Tanese de Souza1, Katherine Baxter1,2, Leonard Angka1,2, Rebecca Xu1, Michael A Kennedy1, Rebecca C Auer1,2,4.   

Abstract

Cancer surgery while necessary for primary tumor removal, has been shown to induce immune suppression and promote metastases in preclinical models and human cancer surgery patients. Activating the immune system and reversing immunosuppression have emerged as promising ways to treat cancer and they can be safely employed in the perioperative period. In this study, we evaluated the immunotherapeutic potential of phosphodiesterase-5 (PDE-5) inhibitors to target surgery-induced myeloid-derived suppressor cells (MDSC) and restore natural killer (NK) cell function in the clinically relevant perioperative period. Immunocompetent murine tumor models of major surgery were used to characterize the functional suppression of surgery-induced MDSC and to assess the in vivo efficacy of perioperative PDE5 inhibition. In cancer surgery patients with abdominal malignancies, we assessed postoperative NK cell function following co-culture with MDSC and PDE5 inhibition. Perioperative PDE5 inhibition reverses surgery-induced immunosuppression. In particular, sildenafil reduces surgery-derived granulocytic-MDSC (gMDSC) function through downregulation of arginase 1 (ARG1), IL4Ra and reactive oxygen species (ROS) expression, enabling NK cell antitumor cytotoxicity and reducing postoperative disease recurrence. By removing surgery-derived immunosuppressive mechanisms of MDSCs, sildenafil can be combined with the administration of perioperative influenza vaccination which targets NK cells to reduce postoperative metastasis. Importantly, sildenafil reverses MDSC suppression in cancer surgery patients. These findings demonstrate that PDE5 inhibitors reduce postoperative metastasis by their ability to inhibit surgery-induced MDSC. Further clinical studies are warranted to investigate the immunotherapeutic role of PDE5 inhibitors in combination with cancer surgery.

Entities:  

Keywords:  NK cell cytotoxicity; Sildenafil; metastases; myeloid derived suppressor cells; postoperative immunosuppression

Year:  2018        PMID: 29872554      PMCID: PMC5980420          DOI: 10.1080/2162402X.2018.1431082

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  43 in total

1.  Regulation of NK cell function by human granulocyte arginase.

Authors:  Johanna Oberlies; Carsten Watzl; Thomas Giese; Claudia Luckner; Pascale Kropf; Ingrid Müller; Anthony D Ho; Markus Munder
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

2.  Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma.

Authors:  Joseph A Califano; Zubair Khan; Kimberly A Noonan; Lakshmi Rudraraju; Zhe Zhang; Hao Wang; Steven Goodman; Christine G Gourin; Patrick K Ha; Carole Fakhry; John Saunders; Marshall Levine; Mei Tang; Geoffrey Neuner; Jeremy D Richmon; Ray Blanco; Nishant Agrawal; Wayne M Koch; Shanthi Marur; Donald T Weed; Paolo Serafini; Ivan Borrello
Journal:  Clin Cancer Res       Date:  2015-01-01       Impact factor: 12.531

3.  Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host.

Authors:  Cunren Liu; Shaohua Yu; John Kappes; Jianhua Wang; William E Grizzle; Kurt R Zinn; Huang-Ge Zhang
Journal:  Blood       Date:  2007-01-23       Impact factor: 22.113

4.  Effect of Ly49 haplotype variance on NK cell function and education.

Authors:  Rajen Patel; Simon Bélanger; Lee-Hwa Tai; Angela D Troke; Andrew P Makrigiannis
Journal:  J Immunol       Date:  2010-09-20       Impact factor: 5.422

5.  Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.

Authors:  Donald T Weed; Paolo Serafini; Jennifer L Vella; Isildinha M Reis; Adriana C De la Fuente; Carmen Gomez; Zoukaa Sargi; Ronen Nazarian; Joseph Califano; Ivan Borrello
Journal:  Clin Cancer Res       Date:  2014-10-15       Impact factor: 12.531

6.  Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells.

Authors:  Lee-Hwa Tai; Christiano Tanese de Souza; Simon Bélanger; Lundi Ly; Almohanad A Alkayyal; Jiqing Zhang; Julia L Rintoul; Abhirami A Ananth; Tiffany Lam; Caroline J Breitbach; Theresa J Falls; David H Kirn; John C Bell; Andrew P Makrigiannis; Rebecca A Auer
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701

7.  Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer.

Authors:  P H Nichols; C W Ramsden; U Ward; P C Sedman; J N Primrose
Journal:  Cancer Res       Date:  1992-10-15       Impact factor: 12.701

8.  Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

Authors:  Hequan Li; Yanmei Han; Qiuli Guo; Minggang Zhang; Xuetao Cao
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

9.  Thermal injury elevates the inflammatory monocyte subpopulation in multiple compartments.

Authors:  John G Noel; Andrew Osterburg; Quan Wang; Xialing Guo; Denise Byrum; Sandy Schwemberger; Holly Goetzman; Charles C Caldwell; Cora K Ogle
Journal:  Shock       Date:  2007-12       Impact factor: 3.454

10.  MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis.

Authors:  Matthew J Delano; Philip O Scumpia; Jason S Weinstein; Dominique Coco; Srinivas Nagaraj; Kindra M Kelly-Scumpia; Kerri A O'Malley; James L Wynn; Svetlana Antonenko; Samer Z Al-Quran; Ryan Swan; Chun-Shiang Chung; Mark A Atkinson; Reuben Ramphal; Dmitry I Gabrilovich; Wesley H Reeves; Alfred Ayala; Joseph Phillips; Drake Laface; Paul G Heyworth; Michael Clare-Salzler; Lyle L Moldawer
Journal:  J Exp Med       Date:  2007-06-04       Impact factor: 14.307

View more
  28 in total

Review 1.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

Review 2.  Lipid Metabolism in Tumor-Associated Natural Killer Cells.

Authors:  Yu Chen; Meihua Sui
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Perioperative arginine prevents metastases by accelerating natural killer cell recovery after surgery.

Authors:  Leonard Angka; Christiano Tanese de Souza; Katherine E Baxter; Sarwat T Khan; Marisa Market; Andre B Martel; Lee-Hwa Tai; Michael A Kennedy; John C Bell; Rebecca C Auer
Journal:  Mol Ther       Date:  2022-05-26       Impact factor: 12.910

Review 4.  Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.

Authors:  Shweta Joshi; Andrew Sharabi
Journal:  Pharmacol Ther       Date:  2022-02-02       Impact factor: 13.400

Review 5.  Lipids in the tumor microenvironment: From cancer progression to treatment.

Authors:  Kevin C Corn; McKenzie A Windham; Marjan Rafat
Journal:  Prog Lipid Res       Date:  2020-08-11       Impact factor: 16.195

Review 6.  Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma.

Authors:  Veethika Pandey; Peter Storz
Journal:  Expert Rev Anticancer Ther       Date:  2019-05-31       Impact factor: 4.512

Review 7.  Repurposing Infectious Diseases Vaccines Against Cancer.

Authors:  Liese Vandeborne; Pan Pantziarka; An M T Van Nuffel; Gauthier Bouche
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

Review 8.  Myeloid derived suppressor cells and the release of micro-metastases from dormancy.

Authors:  Saraswoti Khadge; Kathryn Cole; James E Talmadge
Journal:  Clin Exp Metastasis       Date:  2021-05-20       Impact factor: 4.510

Review 9.  Importance of myeloid derived suppressor cells in cancer from a biomarker perspective.

Authors:  Suresh Gopi Kalathil; Yasmin Thanavala
Journal:  Cell Immunol       Date:  2020-12-31       Impact factor: 4.178

Review 10.  The role of myeloid-derived suppressor cells in hematologic malignancies.

Authors:  Emine Gulsen Gunes; Steven T Rosen; Christiane Querfeld
Journal:  Curr Opin Oncol       Date:  2020-09       Impact factor: 3.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.